Literature DB >> 10103217

Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.

E Bouza1, F Garcia-Garrote, E Cercenado, M Marin, M S Diaz.   

Abstract

We carried out a nationwide study with all of the isolates of Pseudomonas aeruginosa collected in a week in 136 hospitals in Spain. The data on 1,014 isolates included resistance to the following antimicrobials: piperacillin-tazobactam, 7%; meropenem, 8%; amikacin, 9%; tobramycin, 10%; piperacillin, 10%; ticarcillin, 13%; imipenem, 14%; ceftazidime, 15%; cefepime, 17%; ciprofloxacin, 23%; aztreonam, 23%; ofloxacin, 30%; gentamicin, 31%. The most frequent serotypes were O:1 (25.1%), O:4 (21.6%), and O:11 (11.3%).

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10103217      PMCID： PMC89243     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Epidemiological typing of Pseudomonas aeruginosa.

Authors:  T L Pitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

2.  [Prevalence of serotype 0:12 among strains of P. aeruginosa causing nosocomial infection in Spain (1980-1991)].

Authors:  A Vindel; L Azañedo; P Trincado; C Martín-Bourgón
Journal:  Enferm Infecc Microbiol Clin       Date:  1993-01       Impact factor: 1.731

3.  Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group.

Authors:  P T Tassios; V Gennimata; A N Maniatis; C Fock; N J Legakis
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

4.  Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.

Authors:  G Bonfiglio; V Carciotto; G Russo; S Stefani; G C Schito; E Debbia; G Nicoletti
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

5.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

6.  Multiresistant serotype O 12 Pseudomonas aeruginosa: evidence for a common strain in Europe.

Authors:  T L Pitt; D M Livermore; D Pitcher; A C Vatopoulos; N J Legakis
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

7.  Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11.

Authors:  J J Farmer; R A Weinstein; C H Zierdt; C D Brokopp
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948
  7 in total
  20 in total

1.  Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

Authors:  F Luzzaro; E Mantengoli; M Perilli; G Lombardi; V Orlandi; A Orsatti; G Amicosante; G M Rossolini; A Toniolo
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 2.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Relation between chronic obstructive pulmonary disease and antibiotics.

Authors:  Salvador Sialer; Liapikou Adamantia; Mónica Guerrero; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  Biofilm formation, antibiotic susceptibility and RAPD genotypes in Pseudomonas aeruginosa clinical strains isolated from single centre intensive care unit patients.

Authors:  Martina Vaněrková; Barbora Mališová; Iva Kotásková; Veronika Holá; Filip Růžička; Tomáš Freiberger
Journal:  Folia Microbiol (Praha)       Date:  2017-04-01       Impact factor: 2.099

Review 5.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

6.  Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital.

Authors:  Noyal Mariya Joseph; Sheela Devi; P Shashikala; Reba Kanungo
Journal:  J Clin Diagn Res       Date:  2013-10-05

7.  Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.

Authors:  O Gutiérrez; C Juan; E Cercenado; F Navarro; E Bouza; P Coll; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

8.  Magnetically Controlled Carbonate Nanocomposite with Ciprofloxacin for Biofilm Eradication.

Authors:  Viktoriya Rumyantceva; Valeriya Rumyantceva; Yulia Andreeva; Sofia Tsvetikova; Anton Radaev; Maria Vishnevskaya; Vladimir Vinogradov; Andrey S Drozdov; Elena Koshel
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

9.  Pseudomonas bronchopulmonary infections in a palliative care setting.

Authors:  Naveen Salins; Nandini Vallath; Vv Prince
Journal:  Indian J Palliat Care       Date:  2012-01

10.  Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections.

Authors:  Anab Fatima; Syed Baqir Naqvi; Sheikh Abdul Khaliq; Shaheen Perveen; Sabahat Jabeen
Journal:  Springerplus       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.